Medarex - Pipeline

The following tables summarize potential therapeutic indications and development stages for selected antibody products in which Medarex has an economic interest, including our own product candidates and those of our partners (based on publicly available information).

Selected Proprietary and Partnered Product Candidates in Clinical Development

Product Candidate	Indication	Clinical Status	Partner/Licensee
MDX-010 (ipilimumab) anti-CTLA4	Melanoma, Other Cancers	Phase 3 and earlier	Bristol-Myers Squibb Co-promote/Profit share
MDX-060 anti-CD30	Hodgkin's Disease, Anaplastic Large Cell Lymphoma	Phase 2	Wholly-owned
MDX-066 (CDA-1) + MDX-1388 (CDA-2) anti-C. difficile Toxin A and Toxin B	C. difficile Disease	Phase 2	MBL Co-development
MEDI-545 (MDX-1103) anti-IFNα	Lupus	Phase 1	MedImmune/AstraZeneca Co-promote option
MDX-1100 anti-IP10	Ulcerative Colitis	Phase 1	Wholly-owned
MDX-1106 (ONO-4538) anti-PD1	Cancer, Infectious Disease	Phase 1	Ono Pharmaceutical Co-development
MDX-1401 anti-CD30	Cancer	Phase 1	Wholly-owned
MDX-1342 anti-CD19	Chronic Lymphocytic Leukemia, Rheumatoid Arthritis	Phase 1	Wholly-owned
MDX-1411 anti-CD70	Clear Cell Renal Cell Carcinoma	Phase 1	Wholly-owned
MDX-1303 (Valortim^TM) anti-B. anthracis PA	Anthrax	Phase 1	PharmAthene Co-development

Selected Licensee Product Candidates in Clinical Development

Product Candidate	Indication	Clinical Status	Partner/Licensee
CNTO 1275 anti-IL12/IL23	Inflammatory Diseases	BLA Filed	Centocor Milestones/Royalties
CNTO 148 (golimumab) anti-TNFα	Inflammatory Diseases	Phase 3	Centocor Milestones/Royalties
HuMax-CD4 (zanolimumab)* anti-CD4	Cutaneous T-cell Lymphoma	Phase 3 and earlier	Genmab Equity Interest
HuMax-CD20 (ofatumumab) anti-CD20	Lymphomas, Rheumatoid Arthritis	Phase 3 and earlier	Genmab/GlaxoSmithKline Equity Interest
HuMax-EGFR (zalutumumab) anti-EGFR	Head and Neck Cancer	Phase 3 and earlier	Genmab Equity Interest
CP-675,206 (tremelimumab)** anti-CTLA4	Melanoma and Other Cancers	Phase 3 and earlier	Pfizer Royalties
ACZ885 anti-IL1β	Muckle Wells Syndrome	Phase 3	Novartis Pharma Milestones/Royalties
AMGN Antibody #1 Undisclosed	Undisclosed Disease	Phase 2	Amgen Milestones/Royalties
AMGN Antibody #2 Undisclosed	Undisclosed Disease	Phase 2	Amgen Milestones/Royalties
CNTO 95 anti-integrin receptors	Cancer	Phase 2	Centocor Milestones/Royalties
NI-0401 anti-CD3	Crohn's Disease, Renal Transplantation	Phase 1/2	NovImmune Milestones/Royalties
HuMax-IL8 anti-IL8	Palmoplantar Pustulosis	Phase 1/2	Genmab Equity Interest
CDX-1307 anti-Mannose Receptor/hCGβ	Cancer	Phase 1	Celldex Equity Interest
AMG 714 anti-IL15	Inflammatory Disease	Phase 1	Genmab/Amgen Equity Interest
FG-3019 anti-CTGF	Idiopathic Pulmonary Fibrosis, Diabetic Nephropathy	Phase 1	Fibrogen Milestones/Royalties
BMS-66513 Cancer	Cancer	Phase 1	Bristol-Myers Squibb Milestones/Royalties
IMC-18F1 VEGFR-1	Cancer	Phase 1	ImClone Systems Milestones/Royalties
IMC-3G3 anti-PDGFRα	Cancer	Phase 1	ImClone Systems Milestones/Royalties
Anti-VAP1 Antibody anti-VAP1	Inflammatory Disease	Phase 1	BioTie Therapies Milestones/Royalties
NVS Antibody #2 Undisclosed	Autoimmune Disease	Phase 1	Novartis Pharma Milestones/Royalties
AMGN Antibody #3 Undisclosed	Undisclosed Disease	Phase 1	Amgen Milestones/Royalties
AMGN Antibody #4 Undisclosed	Undisclosed Disease	Phase 1	Amgen Milestones/Royalties
AMGN Antibody #5 Undisclosed	Undisclosed Disease	Phase 1	Amgen Milestones/Royalties
LLY Antibody Undisclosed	Undisclosed Disease	Phase 1	Eli Lilly Milestones/Royalties
Roche/Genmab Antibodies Undisclosed	Undisclosed Diseases	Phase 1	Genmab/Roche Equity Interest
Other Undisclosed Antibodies Undisclosed	Undisclosed Diseases	Phase 1	Undisclosed Milestones/Royalties

* In addition to an equity interest in Genmab, Medarex expects to receive milestone payments and up to double-digit royalties in Europe and Asia, should commercialization of zanolimumab occur.

** Medarex expects to receive double-digit royalties on tremelimumab sales, should commercialization occur.